Myopia is increasing at an unprecedented pace worldwide, currently affecting nearly 30 percent of the global population and projected to reach 50 percent by 2050. India reflects this alarming trend. Over the past decade, childhood myopia in urban regions has risen sharply from approximately 7 percent to nearly 21 percent. Importantly, early-onset myopia significantly raises the risk of long-term complications such as retinal detachment, glaucoma, and myopic maculopathy. Therefore, clinicians must ensure accurate and consistent monitoring from an early age.
Clinical Challenges in Pediatric Myopia Management
Despite growing awareness, clinicians continue to face multiple barriers in managing pediatric myopia effectively. First, capturing reliable measurements in young children remains difficult due to poor fixation and limited cooperation. In addition, variability across devices often affects consistency. Moreover, access to axial length measurement tools is largely restricted to tertiary care centers, while high patient volumes lead to long waiting times. As a result, many practices still depend mainly on refraction, which does not adequately reflect true myopia progression.
PRISTINE OBM 12: Addressing Key Gaps in Care
To overcome these challenges, the PRISTINE OBM 12 offers a comprehensive and integrated solution. It combines axial length measurement, full ocular biometry, and autorefraction into a single, automated, child-friendly platform. Within seconds, the device captures 12 essential parameters and seamlessly integrates with EMR systems. Consequently, clinicians can adopt a more objective, evidence-based approach to monitoring myopia progression.
Automation That Improves Accuracy and Efficiency
Furthermore, the PRISTINE OBM 12 uses automatic alignment and intelligent auto-capture to ensure measurements occur only when fixation is accurate. This approach improves repeatability, minimizes operator dependency, and reduces technician workload. By unifying autorefraction and anterior segment biometry into one streamlined workflow, the device also reduces inter-device variability and enhances overall clinic efficiency.
Expanding Access Across Care Settings
In addition, the OBM 12 features a compact design and an intuitive interface, enabling easy deployment across tertiary hospitals, secondary centers, and community clinics. As a result, high-quality pediatric myopia assessment becomes more accessible, even beyond specialized eye care facilities.
Leadership Perspective on Precision and Standardization
Commenting on the innovation, Anand Sivaraman, CEO of Remidio Innovative Solutions, said,
“With the PRISTINE OBM 12, we built precision into every step of the measurement process. Advanced automation—including automated alignment, 3D eye tracking, and intelligent auto-capture—standardizes measurements and minimizes variability. This technology-driven approach improves repeatability, reduces dependence on operator skill, and supports faster, more confident clinical decision-making in pediatric myopia care.”
Clinical Validation from Pediatric Ophthalmology
Echoing this perspective, Dr. Jitendra Jethani, Leading Pediatric Ophthalmologist and Director of Baroda Children Eye Care, stated,
“The PRISTINE OBM 12 represents a meaningful leap in myopia care. Its fully automated acquisition with 3D eye tracking ensures consistently accurate biometry and refraction, even in young children or patients with unstable fixation. By capturing all 12 essential parameters in a single scan, it eliminates operator variability and delivers reliable data under real-world, accommodation-challenging conditions. This level of precision is invaluable for early intervention and long-term myopia management.”
Evidence from Myopia Research
Supporting these clinical insights, Dr. Pavan Verkicharla, Scientist of Myopia Research and Head and Consultant Optometrist at LV Prasad Eye Institute, Hyderabad, emphasized the importance of axial length. He noted,
“Myopia research clearly identifies axial length as a key marker for monitoring progression. In our validation studies, the PRISTINE OBM 12 showed strong agreement with established standard-of-care biometers. Moreover, it demonstrated higher precision compared to manual, non-contact biometers currently available. By integrating axial length, full biometry, and refraction into a single workflow, the device enables more objective monitoring and clearer clinical interpretation, supporting informed long-term myopia management. Importantly, this performance allows high-quality myopia assessment to scale beyond specialist clinics to school screening programs and community settings.”
Strengthening Commitment to Scalable Myopia Care
As per the press release, With the launch of the PRISTINE OBM 12, Remidio reinforces its commitment to developing scalable, clinically robust technologies. By supporting early detection and standardized monitoring, the company addresses one of the fastest-growing global and national public health challenges—pediatric myopia.